Future studies are need to determine if other alterations in CD8 or CD4 extracellular domains could be used to further stabilize the TCR’s interaction with low affinity tumor antigens and thereby improve anti-tumor CD8 and CD4 effects respectively. This evidence concerns the gene CD8A and neoplasm.